Trial Profile
Metabolism and Pharmacokinetics of a Single Dose of 240 mg [14C]-BI 201335 Given as Oral Solution to Healthy Male Volunteers at Steady State of BI 201335 NA Maintained With Oral Capsules of 240 mg BI 201335, a Phase I, Single-arm, Open-label Trial
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Faldaprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 17 Jul 2014 New trial record